A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Stopped Sponsor Decision
Conditions
- HER2-positive Solid Tumors
- HER2-positive Breast Cancer
- HER2-positive Colorectal Cancer
- HER2-positive Gastroesophageal Cancer
- HER2-positive Endometrial Cancer
Interventions
- DRUG: BDC-1001
- DRUG: Nivolumab
Sponsor
Bolt Biotherapeutics, Inc.
Collaborators